Zongertinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.

Journal: Expert opinion on pharmacotherapy
Published: June 18, 2026

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 31, 2026

Robust Findings for HER2 TKI in NSCLC.

Robust Findings for HER2 TKI in NSCLC.

Journal: Cancer discovery
Published: May 02, 2026

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.

Journal: Future oncology (London, England)
Published: April 22, 2026

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine
Published: April 15, 2026

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Journal: Pharmacotherapy
Published: April 10, 2026

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

Journal: International journal of molecular sciences
Published: April 08, 2026

Novel Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy in a Non-Smoking Asian-American Woman Diagnosed With Never-Smoker Non-Small Cell Lung Cancer (NSCLC): A Case Report.

Novel Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy in a Non-Smoking Asian-American Woman Diagnosed With Never-Smoker Non-Small Cell Lung Cancer (NSCLC): A Case Report.

Journal: Cureus
Published: March 27, 2026

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Journal: Investigational new drugs
Published: March 16, 2026

Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.

Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.

Journal: JTO clinical and research reports
Published: March 09, 2026

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Journal: Future oncology (London, England)
Published: March 04, 2026

Successful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer.

Successful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer.

Journal: Respiratory medicine case reports
Published: February 15, 2026
Showing 1-12 of 50

Last Updated: 06/30/2026